Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
D Stolz, T Mkorombindo, DM Schumann, A Agusti… - The Lancet, 2022 - thelancet.com
Executive summary Despite substantial progress in reducing the global impact of many non-
communicable diseases, including heart disease and cancer, morbidity and mortality due to …
communicable diseases, including heart disease and cancer, morbidity and mortality due to …
Nonantimicrobial actions of macrolides: overview and perspectives for future development
JA Kricker, CP Page, FR Gardarsson… - Pharmacological …, 2021 - ASPET
Macrolides are among the most widely prescribed broad spectrum antibacterials, particularly
for respiratory infections. It is now recognized that these drugs, in particular azithromycin …
for respiratory infections. It is now recognized that these drugs, in particular azithromycin …
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
M Bafadhel, S Peterson, MA De Blas… - The Lancet …, 2018 - thelancet.com
Background The peripheral blood eosinophil count might help identify those patients with
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations …
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations …
Inflammatory endotypes in COPD
PJ Barnes - Allergy, 2019 - Wiley Online Library
Chronic obstructive pulmonary disease (COPD) is a major global health problem that is
poorly treated by current therapies as it has proved difficult to treat the underlying …
poorly treated by current therapies as it has proved difficult to treat the underlying …
Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives
P Paliogiannis, AG Fois, S Sotgia… - European …, 2018 - Eur Respiratory Soc
Chronic obstructive pulmonary disease (COPD) is a disabling condition that is characterised
by poorly reversible airflow limitation and inflammation. Acute exacerbations of COPD are a …
by poorly reversible airflow limitation and inflammation. Acute exacerbations of COPD are a …
Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline
JD Chalmers, IF Laska, FME Franssen… - European …, 2020 - Eur Respiratory Soc
Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …
Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study
Background Long-acting β 2 agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are the recommended initial maintenance treatment for chronic obstructive …
(LAMAs) are the recommended initial maintenance treatment for chronic obstructive …
Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice
Background Long-acting β 2-agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …
Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice
Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …